HC Wainwright & Co. Reiterates Buy on Vanda Pharmaceuticals, Maintains $20 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 85.6%

Neg 0% Neu 85.6% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and maintains $20 price target.